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Apathy is a frequent feature of Parkinson’s disease (PD), usually related with executive dysfunction. However, in a subgroup of
PD patients apathy may represent the only or predominant neuropsychiatric feature. To understand the mechanisms underlying
apathy in PD, we investigated emotional processing in PD patients with and without apathy and in healthy controls (HC), assessed
by a facial emotion recognition task (FERT). We excluded PD patients with cognitive impairment, depression, other aﬀective
disturbancesandprevioussurgeryforPD.PDpatientswithapathyscoredsigniﬁcantlyworseintheFERT,performingworseinfear,
anger, and sadness recognition. No diﬀerences, however, were found between nonapathetic PD patients and HC. These ﬁndings
suggest the existence of a disruption of emotional-aﬀective processing in cognitive preserved PD patients with apathy. To identify
speciﬁc dysfunction of limbic structures in PD, patients with isolated apathy may have therapeutic and prognostic implications.
1.Introduction
Apathy has been deﬁned as a lack of motivation evidenced by
diminished goal-directed behavior, cognition, and emotion
[1]. Another deﬁnition, focusing on observable aspects, is
a quantitative reduction of self-generated voluntary and
purposeful behaviors [2].
Apathy is a frequent feature of Parkinson’s disease (PD),
with a prevalence ranging from 5% to 51% of PD patients
[3–9]. Lower prevalence has been observed when patients
with depression or dementia were excluded [8] whereas a
higher prevalence has been reported in samples including
other neuropsychiatric disturbances [6]. Although apathy
and depression frequently coexist in PD, they can develop
separately [5, 6]. Apathy has been consistently reported to be
associated with executive dysfunction [4, 5, 7, 8, 10–12], sug-
gesting that the dysfunction of frontal-subcortical circuits is
common to both phenomena in PD [7, 13, 14]. Nevertheless,
disruption of emotional-aﬀective functional circuits seems
also to be present since the early stages of the disease, and
may play an additional role in the development of apathy in
patients with otherwise no apparent cognitive deﬁcits.
Further insight into the pathophysiology of apathy in PD
should come from studies of cognitively intact patients with
apathy as the only or predominant neuropsychiatric feature.
To the best of our knowledge, apathy has not been formally
assessed in this PD population. More speciﬁcally, emotion
processing has not been evaluated in apathetic PD patients.
We aimed to explore emotion processing, as assessed by a
facial emotion recognition task, in cognitively intact and
nondepressedPDpatientswithandwithoutapathy,matched
for age and educational level.
2. Methods
2.1. Subjects. PD patients fulﬁlling diagnostic criteria for PD
[15] were prospectively recruited from our outpatient Move-
ment Disorders Clinic. Patients with cognitive impairment,2 Parkinson’s Disease
as diagnosed by a score ≥0,5 in the Clinical Dementia Rating
Scale and a score >0 on the UPDRS-cognition item, were
excluded. We excluded also patients with depression (DSM-
IV criteria and a score ≥11 in the Hospital Anxiety and
Depression Scale-HADS) [16], visuoperceptive impairment
(Facial Recognition Test, short form version >20) [17], those
with previous surgery for PD, and those taking drugs with
possible interference in emotion recognition tests such as
beta blockers [18]. Diagnosis of apathy was based on a
clinical interview aiming to identify a reduction of self-
generated voluntary and purposeful behaviors that was
not merely due to the presence of parkinsonian motor
symptoms, and on a score ≥2 on the motivation/initiative
item of the mentation part of the UPDRS [19].
Twelve PD patients with apathy and 19 matched nona-
pathetic PD patients participated in the study after giving
informed consent. All participants were at stable doses of
dopaminergic drugs during the 4 weeks before inclusion. All
PD patients were examined during the “on” state. Motor
status and severity of the disease were assessed by the
motor section of the Uniﬁed Parkinson’s Disease Rating
Scale (UPDRS-III) and Hoehn and Yahr Scale [20]. Global
cognitive function was assessed using the Mattis Dementia
Rating Scale (MDRS) [21].
Sixteen healthy control subjects (HC) participated in the
study. They had no history of neurological or psychiatric
disease and were comparable in age, gender, and education.
No signiﬁcant diﬀerences between groups were found in
clinical or demographical variables (Table 1).
2.2. Facial Emotion Recognition Task. This task is based
on a series of standardized pictures of faces showing six
basic emotions: happiness, sadness, anger, fear, surprise,
and disgust used as facial emotion recognition test (FERT)
(JACFEE) [22]. Thirty-six pictures are included (6 for each
emotion) and played by Caucasian and Oriental actors.
These images were shown without any adaptation, and
displayed on a computer screen (size 20 × 20cm) in a well-
illuminated room. Patients were comfortably seated at a
distance of 45cm of the screen. Subjects’ task is to identify
the emotion portrayed by each face. A brief explanation of
each basic emotion (without showing any image) was done
before starting the test. The faces were presented in random
order. Each image was displayed during 3 seconds. After
each image, a blank screen appeared and subjects had no
time limit to respond. A list with the names of the six basic
emotions was available, in case of word-ﬁnding diﬃculties.
For all patients this was the ﬁrst time receiving a facial
emotion recognition test and no kind of feedback was given
during the task. The percentage of errors committed in the
identiﬁcation of each emotion was recorded.
3.StatisticalAnalysis
Group diﬀerences in demographic, clinical, and cognitive
characteristics were analyzed using a univariate analysis of
variance and χ2 when appropriated. A repeated measures
analysis of variance (ANOVA) was used to test for an
eﬀect of group on the FERT performance. A post hoc
analysis (Scheﬀe) was conducted to identify diﬀerences
between particular subgroups. Associations between FERT
scores and demographic, clinical, and cognitive variables
were analyzed with Spearman’s rank correlations. Variables
showing a signiﬁcant correlation with FERT performance
were included as covariables in a second analysis. The
signiﬁcance level was set at 0.05 for all parameters.
4. Results
Results in the FERT are shown in Table 2.T h ep e r f o r m a n c e s
in the FERT were compared using a repeated measures
analysis of variance, with Huyn-Feldt correction for non-
sphericity. Group (PD patients with apathy, PD patients
without apathy, and healthy controls) was the between-
subject factor, and emotion (happiness, surprise, fear, dis-
gust, anger, and sadness) the within-subject factor. We
observed both a group eﬀect [F(2,44) = 5.877, P =
.005] and an emotion eﬀect [F(4.263,187.556) = 20.10,
P<. 001], with a signiﬁcant interaction between group and
emotion [F(8.525,187.556) = 3.031, P = .003]. Post hoc
analysis showed signiﬁcant diﬀerences between apathetic PD
patients and both nonapathetic patients (P = .012) and HC
(P = .007). No signiﬁcant diﬀerences were observed between
nonapathetic PD patients and HC.
Although no signiﬁcant diﬀerences between groups were
found in clinical and demographical variables, apathetic PD
patients tended to be older, less educated, and with lower
scores in the MDRS, and they also tended to receive lower
doses of dopaminergic treatment. In order to explore the
possible inﬂuence of these variables in the FERT score (in
both apathetic and nonapathetic PD patients), correlations
between FERT global performance and age, years of educa-
tion, MDRS score, and dopaminergic treatment doses were
analyzed. Signiﬁcant correlation was found with age (r =
0.312, P = .033), education (r =− 0.295, P = .046), and
MDRS (r =− 0.455, P = .025). A signiﬁcant group eﬀect
(F = 7.438, P = .013) was still observed after covariance by
age, years of education, and MDRS.
In order to explore whether emotional processing was
homogeneous to all emotions or if the recognition of emo-
tions selectively aﬀected particular emotions, the analysis of
the diﬀerent emotions examined revealed that apathetic PD
patients scored signiﬁcantly worse only in the recognition of
fear (F = 4.948, P = .012) anger (F = 4.393, P = .018), and
sadness (F = 4.447, P = .018).
5. Discussion
The main results of the present study show that PD patients
with apathy exhibit selective deﬁcits in facial emotion
recognition, with more speciﬁc deﬁcits in the recognition of
fear, anger, and sadness. Conversely, nonapathetic patients
recognized facial emotions as accurately as healthy controls.
The exclusion of PD patients with some degree of cog-
nitive impairment, along with the persistence of signiﬁcant
facial emotion recognition diﬀerences between groups afterParkinson’s Disease 3
Table 1: Demographic and clinical characteristics of subject groups.
Characteristics Apathy group Nonapathy group Healthy controls P value
n = 12 n = 19 n = 16
Age (years) 65.67 (4.96) 60.37 (9.38) 60.53 (12.93) .299
Gender (%male) 83.33 68.42 50 .176
Education (years) 9.00 (2.45) 11.52 (5.19) 11.00 (6.29) .349
PD duration (years) 4.83 (2.95) 7.26 (4.26) — .095
Hoehn-Yahr
∗ 2.00 (.00) 2.03 (0.353) — .799
UPDRS motor∗ 20.58 (9.75) 20.77 (5.11) — .944
Motor ﬂuctuations (%) 8.33 42.1 — .085
LDopa eq. dose 699.72 (345.62) 907.56 (537.79) — .309
MDRS score 135.00 (3.71) 137.64 (6.147) — .240
Note that means and standard deviations (in parentheses). Hoehn-Yahr staging ranges from 0 to 6 (most severe); UPDRS motor: motor scale of Uniﬁed
Parkinson’s Disease Rating Scale. Diﬀerence between groups using univariate analysis of variance comparisons or χ2 (gender and motor ﬂuctuations
distribution). ∗Scores obtained from PD patients when they were taking their dopaminergic medications.
Table 2: Errors (%) on the facial emotion recognition test.
Apathy group Nonapathy group Healthy controls P value
(post hoc)
Happiness 13.89 (17.16) 4.38 (7.54) 8.89 (10.66) .097 (0.12)
Surprise 23.61 (18.06) 22.81 (20.19) 25.55 (27.36) .937 (0.96)
Fear 69.44 (28.28) 40.35 (25.04) 36.66 (34.62) .012 (.032)
Disgust 34.72 (20.66) 55.26 (24.25) 46.66 (28.31) .092 (0.14)
Anger 38.89 (22.84) 18.42 (19.95) 18.89 (18.75) .018 (.038)
Sadness 56.94 (33.68) 26.31 (21.74) 35.55 (30.12) .018 (.031)
Total errors 39.35 (7.57) 27.77 (10.55) 28.33 (10.61) .006 (.012)
Note that means and standard deviations (in parentheses). Diﬀerence between groups using univariate analysis of variance comparisons. Post hoc: “P”v a l u e s
after adjusting for age. Education, and MDRS total score.
covariance for MDRS score, education, and age supports the
hypothesis that the diﬀerences observed between apathetic
and nonapathetic patients are not due to task complexities,
but to a diﬀerential impairment of the brain circuits involved
in emotion recognition. Moreover, when recognition of
particular emotions was analyzed, the apathetic group of
PD patients showed a diﬀerent pattern of diﬃculties. As
previously observed, not all basic emotions are as easy to
identify. Fear is often mistaken with surprise, and disgust
with anger [23]. In our sample, fear and disgust were the
most diﬃcult emotions to identify for nonapathetic PD
patients and HC. However, while in apathetic patients fear
recognition was clearly aﬀected, disgust recognition was not
impaired, and deﬁcits in fear, sadness, and anger recognition
were also observed. This ﬁnding reinforces the hypothesis
that emotion recognition defects in apathetic PD patients are
not generalized but restricted to particular emotions.
The use of the FERT precludes a precise identiﬁcation
of the physiopathological correlates of the emotional deﬁcits
observed in our sample. Although limbic structures are
essential in emotion processing, and a link between the
amygdala and fear recognition is well established [24, 25],
facial emotion recognition involves multiple cerebral struc-
tures (visual, somatosensory, prefrontal-orbitofrontal and
ventromedial-cortex, amygdala and basal ganglia) and also
diﬀerent neural processes (categorization of speciﬁc facial
treats, and evocation of associated knowledge, generation of
an emotional response in the observer) [23, 26, 27].
A remarkable observation of this study is the absence of
signiﬁcantdiﬀerencesbetweennonapatheticPDpatientsand
HC in the facial emotion recognition task. Several studies
explored explicit recognition of emotional information in
PD. Overall, previous studies point towards the existence
of deﬁcits in emotion recognition [28–33] that can be
partially reversed by dopaminergic medication [29, 32, 33],
but conﬂicting results have been reported recently [34–36].
These diﬀerences, based on our results, could be due to the
lack of control of the presence of apathy in the patients
explored. While depression has been usually considered as
a confounding factor when assessing the ability to recognize
facial emotions, the lack of control of apathy severity could
account for the diﬀerent results observed in previous studies.
Based on the literature, the lack of signiﬁcant diﬀerences
between nonapathetic PD patients and HC may be due
to several causes. First, dopamine neurotransmission has
been linked to the identiﬁcation of emotions and we cannot
excludeabeneﬁcialeﬀectofmedication.Forinstance,Spren-
gelmeyer et al. compared facial emotion recognition between4 Parkinson’s Disease
16 untreated, early PD patients, 20 treated, more advanced
PD patients, and 40 healthy controls [29]. Although facial
emotion recognition was found to be impaired in both
PD groups, deﬁcits were more consistently noted in the
nonmedicated group. Nonetheless, our results based on a
sample of PD patients studied in their dopaminergic “on”
state,agreewithotherstudies[34,36]whichfailedtoidentify
signiﬁcant evidence of facial emotion recognition impair-
ment in medicated PD patients compared with HC. Second,
the facial emotion expressions used in the present study
were of high intensity. A variety of assessment procedures
for the evaluation of facial emotion expressions recognition
has been used, like expressions of diﬀerent intensities [32]
or tests created on purpose of a speciﬁc study [28, 30].
Suzuki et al. identiﬁed deﬁcits in disgust recognition by
means of a reﬁned test and data analysis while no diﬀerences
were identiﬁed with conventional measures. Third, our
nonapathetic patients were not depressed and were free of
any other neuropsychiatric symptom. Although the relation
betweendepressionandfacialemotionrecognitioninformer
studies is rather inconclusive, it has been negatively related
with the recognition of fear [28]. Finally, a small sample
s i z ea n dab r i e fF E R Tm a yh a v ed i ﬃcult identiﬁcation of
signiﬁcantdiﬀerencesbetweennonapatheticPDpatientsand
HC.
Despite the exploratory character of this study, our
results point towards a possible existence of a disruption
of emotional-aﬀective processing in cognitively intact PD
patients with apathy. Further studies, assessing the early
processing of emotional information, are needed to investi-
gate the physiopathological correlates of the facial emotion
recognition deﬁcits observed in apathetic PD patients. To
identify a speciﬁc dysfunction of limbic structures in PD
patients with isolated apathy may have therapeutic and
prognostic implications.
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